scispace - formally typeset
A

Aimee W. Kao

Researcher at University of California, San Francisco

Publications -  51
Citations -  2754

Aimee W. Kao is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Neurodegeneration & Frontotemporal lobar degeneration. The author has an hindex of 23, co-authored 45 publications receiving 2205 citations. Previous affiliations of Aimee W. Kao include University of Iowa.

Papers
More filters
Journal ArticleDOI

Inhibition of Clathrin-Mediated Endocytosis Selectively Attenuates Specific Insulin Receptor Signal Transduction Pathways

TL;DR: The data demonstrate that the acute actions of insulin are largely independent of insulin receptor endocytosis and are initiated by activation of the plasma membrane-localized insulin receptor.
Journal ArticleDOI

Dynamin Is Required for Recombinant Adeno-Associated Virus Type 2 Infection

TL;DR: It is demonstrated that rAAV-2 infection is partially dependent on dynamin function, a GTPase protein involved in clathrin-mediated internalization of receptors and their ligands from the plasma membrane.
Journal ArticleDOI

The Role of Glycogen Synthase Kinase 3β in Insulin-stimulated Glucose Metabolism

TL;DR: The hypothesis that GSK3β contributes to insulin regulation of glycogen synthesis, but is not responsible for the increase in glucose transport is supported.
Journal ArticleDOI

Clinicopathological correlations in behavioural variant frontotemporal dementia.

TL;DR: In this paper, the authors explored clinicopathological correlations in a large bvFTD cohort and used a combination of known predictive factors (genetic mutations, motor features, or striking atrophy patterns) and the results of a discriminant function analysis that incorporated clinical, neuroimaging and neuropsychological data.
Journal ArticleDOI

Progranulin, lysosomal regulation and neurodegenerative disease

TL;DR: Recent advances in progranulin biology are reviewed, emphasizing its roles in lysosomal function and brain innate immunity, and future avenues of investigation that may lead to new therapeutic approaches for neurodegeneration are outlined.